Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

被引：0
|
作者：
Pagani, Olivia
Regan, Meredith M.
Walley, Barbara
Fleming, Gini F.
Colleoni, Marco
Lang, Istvan
Gomez, Henry Leonidas
Tondini, Carlo
Burstein, Harold J.
Perez, Edith A.
Ciruelos, Eva
Stearns, Vered
Bonnefoi, Herve R.
Martino, Silvana
Geyer, Charles E.
Rabaglio-Poretti, Manuela
Coates, Alan S.
Gelber, Richard D.
Goldhirsch, Aron
Francis, Prudence A.
机构：
[1] SAKK, Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[2] IBCSG, Lugano Viganello, Switzerland
[3] Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA
[4] NCIC Clin Trials Grp, Kingston, ON, Canada
[5] Univ Chicago, Med Ctr & Alliance, Chicago, IL 60637 USA
[6] European Inst Oncol, Milan, Italy
[7] IBCSG, Milan, Italy
[8] Natl Inst Oncol, Budapest, Hungary
[9] Inst Natl Enfermedades Neoplas, Lima, Peru
[10] IBCSG, Lima, Peru
[11] Osp Papa Giovanni XXIII, Bergamo, Italy
[12] Dana Farber Canc Inst & Alliance, Boston, MA USA
[13] Mayo Clin & Alliance, Jacksonville, FL USA
[14] Univ Hosp 12 Octubre, Madrid, Spain
[15] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[16] ECOG, Baltimore, MD USA
[17] Bergonie Inst, Bordeaux, France
[18] EORTC, Bordeaux, France
[19] Angeles Clin & Res Inst, Santa Monica, CA USA
[20] SWOG, Santa Monica, CA USA
[21] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA USA
[22] NRG Oncol, Richmond, VA USA
[23] Inst Med Oncol, Bern, Switzerland
[24] Int Breast Canc Study Grp, Bern, Switzerland
[25] ANZBCTG, Peter MacCallurn Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): joint analysis of IBCSG TEXT and SOFT trials.
    Pagani, Olivia
    Regan, Meredith M.
    Walley, Barbara
    Fleming, Gini F.
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry Leonidas
    Tondini, Carlo
    Burstein, Harold J.
    Perez, Edith A.
    Ciruelos, Eva
    Stearns, Vered
    Bonnefoi, Nerve R.
    Martino, Silvana
    Geyer, Charles E.
    Rabaglio-Poretti, Manuela
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Francis, Prudence A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): update of the combined TEXT and SOFT trials
    Regan, Meredith M.
    Walley, Barbara A.
    Fleming, Gini F.
    Francis, Prudence A.
    Colleoni, Marco A.
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo A.
    Burstein, Harold J.
    Goetz, Matthew P.
    Ciruelos, Eva M.
    Stearns, Vered
    Bonnefoi, Herve R.
    Martino, Silvana
    Geyer, Charles E., Jr.
    Chini, Claudio
    Minisini, Alessandro M.
    Spazzapan, Simon
    Ruhstaller, Thomas
    Winer, Eric P.
    Ruepp, Barbara
    Loi, Sherene
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Pagani, Olivia
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR plus ) early breast cancer (BC): Update of the combined TEXT and SOFT trials
    Pagani, Olivia
    Regan, Meredith M.
    Fleming, Gini F.
    Walley, Barbara A.
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo
    Burstein, Harold J.
    Goetz, Matthew P.
    Ciruelos, Eva M.
    Stearns, Vered
    Debled, Marc
    Martino, Silvana
    Geyer, Charles E., Jr.
    Pinotti, Graziella
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Francis, Prudence A.
    CANCER RESEARCH, 2018, 78 (04)
  • [4] Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Analysis of the SOFT trial
    Goldhirsch, Aron
    Gelber, Richard D.
    Francis, Prudence A.
    Regan, Meredith M.
    Fleming, Gini F.
    Lang, Istvan
    Ciruelos, Eva M.
    Bellet, Meritxell
    Bonnefoi, Herve
    Climent, Miguel A.
    Pavesi, Lorenzo
    Burstein, Harold J.
    Martino, Silvana
    Davidson, Nancy E.
    Geyer, Charles E., Jr.
    Walley, Barbara A.
    Coleman, Robert E.
    Kerbrat, Pierre
    Rabaglio-Poretti, Manuela
    Coates, Alan S.
    CANCER RESEARCH, 2015, 75
  • [5] Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Update of the SOFT trial
    Fleming, Gini
    Francis, Prudence A.
    Lang, Istvan
    Ciruelos, Eva M.
    Bellet, Meritxell
    Bonnefoi, Herve R.
    Climent, Miguel A.
    Pavesi, Lorenzo
    Burstein, Harold J.
    Martino, Silvana
    Davidson, Nancy E.
    Geyer, Charles E., Jr.
    Walley, Babara A.
    Coleman, Robert E.
    Kerbrat, Pierre
    Buchholz, Stefan
    Ingle, James N.
    Rabaglio-Poretti, Manuela
    Colleoni, Marco
    Regan, Meredith M.
    CANCER RESEARCH, 2018, 78 (04)
  • [6] Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC)
    Bernhard, Juerg
    Luo, Weixiu
    Ribi, Karin
    Eon, Marco Col
    Burstein, Harold J.
    Tondini, Carlo
    Pinotti, Graziella
    Spazzapan, Simon
    Ruhstaller, Thomas
    Puglisi, Fabio
    Paves, Lorenzo
    Parmar, Vani
    Regan, Meredith M.
    Pagani, Olivia
    Fleming, Gini F.
    Francis, Prudence A.
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Walley, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR plus ) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
    Tesch, Megan Elizabeth
    Zheng, Yue
    Rosenberg, Shoshana M.
    Poorvu, Philip Daniel
    Ruddy, Kathryn Jean
    Tamimi, Rulla
    Schapira, Lidia
    Peppercorn, Jeffrey M.
    Borges, Virginia F.
    Come, Steven E.
    Snow, Craig
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] SOFT and TEXT: Trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor -positive early breast cancer
    Zickl, L.
    Francis, P.
    Fleming, G.
    Pagani, O.
    Walley, B.
    Price, K. N.
    Gelber, R. D.
    Regan, M. M.
    CANCER RESEARCH, 2012, 72
  • [9] Predictors of Incomplete Ovarian Function Suppression (OFS) in Adolescent and Young Adult (AYA) Women with Hormone Receptor Positive (HR plus ) Breast Cancer
    Anandan, Apoorva
    Ghosh, Trinetri
    Zhao, Jiwei
    Wisinski, Kari B.
    CANCER RESEARCH, 2023, 83 (05)
  • [10] Adjuvant ovarian suppression plus aromatase inhibitor or tamoxifen for hormone receptor-positive breast cancer in women younger than 35 (ASPAIT): A multicenter randomized clinical trial
    Shan, Zhen
    Shao, Nan
    Yuan, Zhongyu
    Chen, Qianjun
    Zhang, Anqin
    Wang, Kun
    Zhang, Ailing
    Cai, Li
    Song, Yuhua
    Yao, Herui
    Ma, Hongmin
    Huang, Heng
    Li, Jianwen
    Zhang, Yuanqi
    Zhang, Lehong
    Zhong, Jincai
    Liu, Hui
    Wu, Zhiyong
    Zhao, Li
    Ling, Feihai
    Yang, Weixiong
    Zhuo, Rui
    Song, Xiangyang
    Lin, Ying
    CANCER RESEARCH, 2020, 80 (04)
12345